Compound Compare is a page on Amino Axiom, a free research information platform that also hosts a compound library, a vendor directory, price comparison, a glossary and keyword search. The page places two compounds next to each other and lines up their structural attributes and the research literature associated with each. It lives at Compound Compare.
It is a reading aid. It does not rank compounds or say which one is better, and it makes no claim about what either molecule does outside a controlled laboratory setting. The value for a researcher is that two entries that would otherwise sit in separate tabs are laid out in one view, with the same fields in the same order.
Why does a side-by-side view matter for incretin research?
Side-by-side comparison matters because the incretin field has many related scaffolds whose differences are easy to lose when entries sit in separate tabs. A shared layout makes differences in length, mass and composition visible at once and moves effort from transcription to assay design.
The incretin field is organized around a small number of receptor targets and a growing family of scaffolds that engage them in different combinations. Native GLP-1 acts on a single receptor. Lipidated analogs such as GLP-1(S) were built to change the physical properties of the molecule. Newer multi-receptor scaffolds such as GLP-3(R) engage more than one target. A reviewer who wants to understand how these relate usually ends up building a table by hand, copying values from several sources and hoping they are consistent.
A comparison view removes the copying step. Differences in length, mass and composition are visible at once, and the researcher can concentrate on what those differences imply for assay design rather than on transcription.
What does the comparison actually show?
Amino Axiom's comparison page has two halves: a structural half that lists attributes of each compound in parallel rows, and a literature half that summarizes published research for each. Both halves use the same fields in the same order for both compounds, so differences are visible without switching tabs.
The page has two halves. The structural half lists attributes of each compound in parallel rows, such as the sequence or scaffold description, the molecular formula and the molecular weight. The literature half summarizes the published research associated with each compound, so a reader can see what kinds of studies exist for one but not the other.
Taking the catalog values on this site as the reference, native GLP-1 is listed at 3337.73 g/mol with a formula of C151H226N40O46. GLP-1(S) is listed at 4113.58 g/mol with C187H291N45O59. GLP-3(R) is listed at 4731.33 g/mol with C221H342N46O68. Placed in adjacent columns, the progression is easy to see: each step adds mass, and the added mass reflects added structure, such as a fatty di-acid side chain or a longer backbone.
The table below shows the same pattern for three of this brand's catalog compounds, using only catalog values.
Any value on the page should still be checked against a primary source before it goes into a protocol or a manuscript. The tool summarizes; it does not replace a certificate of analysis or a published characterization.
How would an incretin lab read a pairing?
Consider a hypothetical receptor binding and cAMP signaling study that uses native GLP-1 as the reference ligand and GLP-1(S) as a test ligand. A reasonable reading sequence is:
Select the two compounds and open the comparison.
Read the structural rows first. Note the difference in molecular weight, roughly 776 g/mol between the two catalog values, and ask what structural feature accounts for it.
Read the literature half. Note which assay formats appear for each compound and whether the same cell systems are used.
Write down the gaps. If the literature for one compound uses a different readout than the other, a head-to-head assay will need its own controls.
Return to the catalog entries for each compound and confirm the identifiers the lab holds.
The weight difference in step 2 is arithmetic, not a finding. The comparison page makes the arithmetic quick, and the interpretation stays with the researcher.
What changes when one compound is a multi-receptor scaffold?
Pairing a single-target reference with a multi-receptor scaffold raises design questions that a single-target pairing does not. If the study compares native GLP-1 with GLP-3(R), the second compound can engage receptors the first does not, so any difference in a cell-based readout may come from receptor expression in the chosen cell line rather than from the ligands themselves.
The comparison page cannot answer that, but it helps frame it. By showing the two scaffolds together, it makes clear that the study is not comparing like with like, and that the receptor panel in the assay system needs to be characterized before the data are read. A lab might respond by using receptor-null and single-receptor-expressing lines as controls, and by recording expression levels alongside the results.
A second pairing worth examining is between two members of the same broad family with different masses, for example GLP-2(T), listed at 4813.53 g/mol with a formula of C225H348N48O68, and GLP-3(R). The masses differ by about 82 g/mol, and the formulas differ in nearly every element count. That alone suggests the two are distinct chemical entities with distinct synthesis and purification profiles, which matters when planning identity confirmation.
How does the comparison connect to analytical work?
Molecular weight and formula in a comparison view serve a second purpose: they are the expected values for identity checks. An intact mass measurement by liquid chromatography and mass spectrometry should deconvolute to the listed mass within instrument tolerance. When a lab runs several incretin-class compounds in one program, having the expected masses side by side makes it easier to spot a mix-up, for instance when two samples have been swapped or when a lot shows a mass that matches a related compound rather than the intended one.
Purity profiles for long synthetic peptides are shaped by their length and modifications. Truncation products, oxidized residues and incompletely modified species are all possible. A comparison page does not report lot-level purity, since that belongs to the certificate and to the lab's own chromatography, but seeing the structural complexity of each molecule in one place helps set expectations for what an acceptable chromatogram might look like.
What are the limits of a comparison tool?
A comparison tool is limited by the completeness of the entries behind it, by the way parallel rows flatten differences in importance, and by the fact that it is descriptive rather than evaluative. Three limits are worth stating plainly.
First, a comparison is only as complete as the entries behind it. If the literature on one compound is thin, the page will show a thin column, and that is information about the state of the literature rather than about the compound.
Second, parallel rows invite the impression that differences are equivalent in importance. A mass difference and a difference in receptor selectivity are not the same kind of fact, and only the second has direct bearing on pharmacology. The reader has to supply that weighting.
Third, the page is descriptive. Whether a scaffold has a particular affinity, efficacy or selectivity is a question for published pharmacology and for the lab's own assays.
Where does this fit in a research workflow?
The natural place for the tool is early in study design, when a lab is choosing which compounds to include and what controls each one needs. A researcher can open a pairing, record the structural differences in the project notes, and use them to decide on assay formats, mass spectrometry targets and bridging controls. Later, when writing up, the same view is a convenient place to check that the compounds described in a methods section are distinguished clearly from one another.
The platform's homepage at Amino Axiom lists the other surfaces available alongside the comparison page. For this article the relevant one is the comparison view, and the walkthrough above is meant to show how its rows can be read as context for incretin work.
Research use disclaimer
All compounds referenced in this article are supplied for laboratory research use only. They are not intended for human or veterinary use, and nothing here describes or implies any use outside in vitro and other controlled research settings. Descriptions of Amino Axiom reflect only what its Compound Compare page visibly presents. For research purposes only.
Reference
Common questions
Compound Compare shows two research compounds side by side, with structural attributes such as formula and molecular weight in parallel rows and a summary of the published literature for each. It does not rank compounds or say which is better. It is a reading aid, and values should still be checked against primary sources.
Yes. Any two compounds in the library can be placed together, including a single-target reference such as native GLP-1 and a multi-receptor scaffold such as GLP-3(R). The page frames the structural differences, but receptor selectivity and assay behavior must come from published pharmacology and the lab's own controls.
No. The comparison page shows catalog-level structural values and literature summaries, not lot-level data. Purity, identity by mass spectrometry and other lot-specific results belong on the certificate of analysis and in the laboratory's own chromatography. The expected masses shown can serve as a reference when checking a lot.
Molecular weight is the expected value for an intact mass measurement, so comparing it across compounds helps a lab spot sample mix-ups and plan identity checks. In the catalog, GLP-1 is 3337.73 g/mol and GLP-1(S) is 4113.58 g/mol, a difference of roughly 776 g/mol that reflects added structure.
